Azura Ophthalmics

Developing therapies for meibomian gland dysfunction

placeTel Aviv, Tel Aviv, Israel calendar_todayFounded 1997 groups11 employees language azuraophthalmics.com

Innovation

29 patent families (11 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 2,655 times.

YearFilings
20173
20184
20194
202010
202115
202216
202313
202415
202513
20264

Social engagement

Social engagement: 2K social following, 7 posts in the last 12 months — below the industry typical range.

Investor mix

6 investors on record; lead investors include Ganot Capital, Elron Electronic Industries, Orbimed, Medical Research Commercialisation Fund.

Investor typeCountShare
Venture capital350%
Private equity233%
Other / undisclosed117%

Recent activity

6 May 2026
Event
ARVO 2026
24 Apr 2026
Event
ARVO Annual Meeting 2026
7 Jan 2026
Event
44th Annual J.P. Morgan Healthcare Conference
Coming soon